Characterization of <i>TP53</i> mutations in actionable driver-negative non-small cell lung cancer (NSCLC).Jie Chi, Hirva Mamdani, Stephen V. Liu et al.|Journal of Clinical Oncology|2024Cited by 4
Association of PAK4 expression with overall survival in patients with non-small cell lung cancer (NSCLC).Hirva Mamdani, Asfar S. Azmi, Sharon Wu et al.|Journal of Clinical Oncology|2022Cited by 2
Co-mutational status and PD-L1 expression in <i>KRAS</i> mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.Hina Khan, Nagla Fawzy Abdel Karim, Julia Judd et al.|Journal of Clinical Oncology|2023Cited by 2
1066P Tumor microenvironment (TME) of HRAS mutated non-small cell lung cancer (NSCLC)Asaad Trabolsi, G. Lopes, Stephen V. Liu et al.|Annals of Oncology|2022Cited by 0